Sanjay Mehta
Experienced in Hepatitis C

Dr. Sanjay Mehta

Infectious Disease
UC San Diego Student Health SVC Pharmacy
9500 Gilman Dr, 
La Jolla, CA 
Experienced in Hepatitis C
UC San Diego Student Health SVC Pharmacy
9500 Gilman Dr, 
La Jolla, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Sanjay Mehta is an Infectious Disease provider in La Jolla, California. Dr. Mehta is rated as an Experienced provider by MediFind in the treatment of Hepatitis C. His top areas of expertise are HIV/AIDS, Sepsis, Severe Acute Respiratory Syndrome (SARS), and Gonorrhea.

His clinical research consists of co-authoring 187 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 4 articles in the study of Hepatitis C.

Specialties
Infectious Disease
Licenses
Internal Medicine in CA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID

Locations

UC San Diego Student Health SVC Pharmacy
9500 Gilman Dr, La Jolla, CA 92093

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
Enrollment Status: Completed
Publish Date: February 06, 2026
Intervention Type: Drug
Study Drug: Ralinepag
Study Phase: Phase 3
An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
Enrollment Status: Terminated
Publish Date: June 11, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension
Enrollment Status: Terminated
Publish Date: June 04, 2025
Intervention Type: Drug
Study Phase: Phase 3
Study of Angiogenic Cell Therapy for Progressive Pulmonary Hypertension: Intervention With Repeat Dosing of eNOS-enhanced EPCs
Study of Angiogenic Cell Therapy for Progressive Pulmonary Hypertension: Intervention With Repeat Dosing of eNOS-enhanced EPCs
Enrollment Status: Terminated
Publish Date: January 31, 2025
Intervention Type: Biological
Study Drug: Autologous EPCs transfected with human eNOS
Study Phase: Phase 2/Phase 3
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Ralinepag to Evaluate Safety and Effects on Exercise Capacity Assessed by CPET in Subjects With WHO Group 1 Pulmonary Hypertension Who Recently Initiated Therapy
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Ralinepag to Evaluate Safety and Effects on Exercise Capacity Assessed by CPET in Subjects With WHO Group 1 Pulmonary Hypertension Who Recently Initiated Therapy
Enrollment Status: Terminated
Publish Date: October 24, 2023
Intervention Type: Drug
Study Drug: Ralinepag
Study Phase: Phase 3
Open-Label Extension Study of UT-15C in Subjects With Pulmonary Arterial Hypertension- A Long-Term Follow-Up to Protocol TDE-PH-310
Open-Label Extension Study of UT-15C in Subjects With Pulmonary Arterial Hypertension- A Long-Term Follow-Up to Protocol TDE-PH-310
Enrollment Status: Completed
Publish Date: June 02, 2022
Intervention Type: Drug
Study Drug: UT-15C
Study Phase: Phase 3
A Phase 2a, Double-Blind, Placebo-Controlled Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of RVT-1201 in Patients With Pulmonary Arterial Hypertension
A Phase 2a, Double-Blind, Placebo-Controlled Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of RVT-1201 in Patients With Pulmonary Arterial Hypertension
Enrollment Status: Terminated
Publish Date: March 09, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects With Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy
A Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects With Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy
Enrollment Status: Completed
Publish Date: February 13, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 7 Less Clinical Trials

187 Total Publications

Clinician perspectives on disclosing public health uses of HIV antiretroviral resistance testing results.
Clinician perspectives on disclosing public health uses of HIV antiretroviral resistance testing results.
Journal: Journal of acquired immune deficiency syndromes (1999)
Published: June 12, 2025
Similar Doctors
Distinguished in Hepatitis C
Dr. Edward Cachay
Infectious Disease
Distinguished in Hepatitis C
Dr. Edward Cachay
Infectious Disease

UC San Diego

200 W Arbor Dr, 
San Diego, CA 
 (86.6 miles away)
619-543-3995
Languages Spoken:
English
See accepted insurances

Edward Cachay is an Infectious Disease provider in San Diego, California. Dr. Cachay is rated as a Distinguished provider by MediFind in the treatment of Hepatitis C. His top areas of expertise are HIV/AIDS, Hepatitis C, Hepatitis, and Myelitis.

Advanced in Hepatitis C
Dr. Francesca Torriani
Infectious Disease
Advanced in Hepatitis C
Dr. Francesca Torriani
Infectious Disease

UC San Diego

200 W Arbor Dr, 
San Diego, CA 
 (86.6 miles away)
619-543-8258
Languages Spoken:
English

Francesca Torriani is an Infectious Disease provider in San Diego, California. Dr. Torriani is rated as an Advanced provider by MediFind in the treatment of Hepatitis C. Her top areas of expertise are Hepatitis, Hepatitis C, Sepsis, and HIV/AIDS.

Advanced in Hepatitis C
Dr. Saima Aslam
Infectious Disease
Advanced in Hepatitis C
Dr. Saima Aslam
Infectious Disease

UC San Diego

200 W Arbor Dr, 
San Diego, CA 
 (86.6 miles away)
619-543-6146
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Saima Aslam is an Infectious Disease provider in San Diego, California. Dr. Aslam is rated as an Advanced provider by MediFind in the treatment of Hepatitis C. Her top areas of expertise are Cryptococcosis, Cystoisosporiasis, Sepsis, Cytomegalovirus Infection, and Hormone Replacement Therapy (HRT).

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mehta's expertise for a condition
ConditionClose
    View All 16 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile